Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
Indomethacin testing in suspected paroxysmal hemicrania and hemicrania continua: Clinical phenotypes and response patterns in a tertiary headache centre.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bender Antoine, Muresan Mirela, Joganah Lauriane, Salvat Eric
Аннотация
BACKGROUND: Indomethacin responsiveness is considered the defining diagnostic feature of hemicrania continua and paroxysmal hemicrania. However, the clinical presentation of indomethacin-responsive headaches is often heterogeneous, and practical guidance regarding which patients should undergo an indomethacin trial, the optimal duration of treatment, and the interpretation of partial responses remains limited.
CASES: Eighteen patients underwent an indomethacin trial in our pain centre over the last year, of whom eleven (61%) achieved a positive response. Positive responders included patients ultimately diagnosed with probable or definite hemicrania continua (n = 6); and probable or definite paroxysmal hemicrania (n = 5), including secondary forms. Clinical presentations frequently departed from ICHD-3 criteria. Trigeminal autonomic symptoms were absent in several responders, while migrainous features were common. Attack duration in patients with paroxysmal hemicrania frequently exceeded the 30-min upper limit defined by ICHD-3, and some patients presented with pain characteristics suggestive of neuropathic disorders. The median time to a clinically meaningful response was 13 days for hemicrania continua (range 3-35 days) and 11 days for paroxysmal hemicrania (range 4-23 days). Most patients responded to 150 mg/day, although escalation to 225 mg/day or prolonged treatment exceeding four weeks was occasionally required. Seven patients had negative trials, leading to alternative diagnoses including migraine, cluster headache, SUNA, post-traumatic headache, and idiopathic mandibular neuropathy.
CONCLUSIONS: This case series illustrates the broad clinical spectrum of indomethacin-responsive headaches and highlights the limitations of relying exclusively on ICHD-3 criteria when selecting patients for an indomethacin trial. Clinical suspicion should remain broad, particularly in patients with strictly unilateral headaches, atypical trigeminal autonomic cephalalgias, or refractory unilateral primary headaches.
CASES: Eighteen patients underwent an indomethacin trial in our pain centre over the last year, of whom eleven (61%) achieved a positive response. Positive responders included patients ultimately diagnosed with probable or definite hemicrania continua (n = 6); and probable or definite paroxysmal hemicrania (n = 5), including secondary forms. Clinical presentations frequently departed from ICHD-3 criteria. Trigeminal autonomic symptoms were absent in several responders, while migrainous features were common. Attack duration in patients with paroxysmal hemicrania frequently exceeded the 30-min upper limit defined by ICHD-3, and some patients presented with pain characteristics suggestive of neuropathic disorders. The median time to a clinically meaningful response was 13 days for hemicrania continua (range 3-35 days) and 11 days for paroxysmal hemicrania (range 4-23 days). Most patients responded to 150 mg/day, although escalation to 225 mg/day or prolonged treatment exceeding four weeks was occasionally required. Seven patients had negative trials, leading to alternative diagnoses including migraine, cluster headache, SUNA, post-traumatic headache, and idiopathic mandibular neuropathy.
CONCLUSIONS: This case series illustrates the broad clinical spectrum of indomethacin-responsive headaches and highlights the limitations of relying exclusively on ICHD-3 criteria when selecting patients for an indomethacin trial. Clinical suspicion should remain broad, particularly in patients with strictly unilateral headaches, atypical trigeminal autonomic cephalalgias, or refractory unilateral primary headaches.